• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of the new cancer immunotherapy using iPS-DC which inhibited immune checkpoint

Research Project

Project/Area Number 17K10521
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field General surgery
Research InstitutionWakayama Medical University

Principal Investigator

Nakamura Masaki  和歌山県立医科大学, 医学部, 准教授 (80364090)

Co-Investigator(Kenkyū-buntansha) 中森 幹人  和歌山県立医科大学, 医学部, 非常勤講師 (10322372)
山上 裕機  和歌山県立医科大学, 医学部, 教授 (20191190)
尾島 敏康  和歌山県立医科大学, 医学部, 講師 (60448785)
Project Period (FY) 2017-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Keywords樹状細胞 / iPS細胞 / 癌免疫療法 / 免疫チェックポイント
Outline of Final Research Achievements

In the present study, we induced the iPSDCs from gastrointestinal solid cancer patients, and compared those iPSCs with MoDC from those patients. Moreover, we improved cancer peptide vaccination by targeting Ag peptides selectively to a DC subset, XCR1-expressing DCs (XCR1+ DCs), with high ability to support CD8+ T-cell responses. We have generated a fusion protein, consisting of an Ag peptide presented with MHC class I, and an XCR1 ligand, XCL1, and examined its effects on antitumour immunity in mice. Our results showed that the iPSCs from gastrointestinal solid cancer patients had increased cytokine production and migration ability compared to MoDC from those patients. Moreover, we showed that the fusion protein plus poly(I:C) inhibited the tumor growth efficiently in the prophylactic and therapeutic tumor models. Furthermore, the fusion protein plus poly(I:C) showed suppressive effects on tumor growth in synergy with anti-PD-1 Ab.

Academic Significance and Societal Importance of the Research Achievements

本研究では、消化器固形癌患者から樹立したiPS細胞からDC(iPSDC)を分化誘導し、その機能を明らかにした。さらに細胞傷害性T細胞(CTL)誘導能の高いペプチドワクチンの作成に成功し、免疫チェックポイント阻害併用による腫瘍増殖抑制の上乗せ効果を証明した。本研究の結果は、ヒト消化器癌に対する免疫チェックポイント阻害機構を併用したDCワクチン療法の臨床応用を立ち上げることにおいて極めて重要な根拠となると考える。

Report

(4 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (2 results)

All 2019

All Presentation (2 results)

  • [Presentation] iPS細胞由来樹状細胞を用いた新規癌ワクチン療法の構築2019

    • Author(s)
      尾島 敏康
    • Organizer
      第119回日本外科学会定期学術集会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 消化器癌患者におけるiPS細胞由来樹状細胞(iPSDC)を用いた新規オーダーメイドワクチン療法の基礎的検討2019

    • Author(s)
      田端宏尭
    • Organizer
      第40回癌免疫外科研究会
    • Related Report
      2019 Annual Research Report

URL: 

Published: 2017-04-28   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi